Get the Stockscreener App
2.835
5.18%
-0.155
Humacyte Inc stock is traded at $2.835, with a volume of 386.74K.
It is down -5.18% in the last 24 hours and down -27.68% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
See More
Previous Close:
$2.99
Open:
$2.96
24h Volume:
386.74K
Relative Volume:
0.10
Market Cap:
$385.36M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-2.6495
EPS:
-1.07
Net Cash Flow:
$-75.59M
1W Performance:
-4.22%
1M Performance:
-27.68%
6M Performance:
-49.73%
1Y Performance:
-13.83%
1-Day Range:
$2.81
$3.005
1-Week Range:
$2.81
$3.11
52-Week Range:
$2.81
$9.97
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
2.836 | 385.36M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.81 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.98 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
578.98 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.67 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.16 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why - Nasdaq
Humacyte’s Symvess: A Transformative Solution in Vascular Trauma Care with Strong Market Potential - TipRanks
Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics - The Manila Times
Humacyte Announces Economic Value of Symvess in Budget Impact Model Publication - Nasdaq
New Study: Humacyte's Symvess Cuts Trauma Center Costs by $33,000 Per Patient - StockTitan
Humacyte’s SYMVESS Launch and Strategic Positioning Drive Buy Rating - TipRanks
Humacyte (NASDAQ:HUMA) Earns Buy Rating from D. Boral Capital - Defense World
Rhumbline Advisers Acquires 5,005 Shares of Humacyte, Inc. (NASDAQ:HUMA) - Defense World
Benchmark maintains Humacyte stock Buy rating, $17 target - Investing.com India
Benchmark maintains Humacyte stock Buy rating, $17 target By Investing.com - Investing.com South Africa
Humacyte, Inc. (NASDAQ:HUMA) Receives $13.71 Average Target Price from Analysts - Defense World
Humacyte Partners With Trestle Biotherapeutics on Bioengineered Kidney Research -March 06, 2025 at 09:16 am EST - Marketscreener.com
Humacyte, Trestle Biotherapeutics announce research collaboration - TipRanks
Can This Groundbreaking Biotech Partnership Solve the Kidney Transplant Crisis? - StockTitan
Trestle Bio Announces Research Collaboration with Humacyte - The Bakersfield Californian
Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade - MSN
Levi & Korsinsky Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025HUMA - ACCESS Newswire
Shareholders that Lost Money on Humacyte, Inc. (HUMA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025 - The Manila Times
Will Humacyte's First-in-Class Bioengineered Vessel Transform Trauma Care? Investors to Get Answers - StockTitan
Atria Wealth Solutions Inc. Makes New Investment in Humacyte, Inc. (NASDAQ:HUMA) - Defense World
Buy Rating for Humacyte Driven by Symvess Launch and Economic Advantages - TipRanks
Humacyte, Inc. Class Action: Levi & Korsinsky Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025HUMA - ACCESS Newswire
Shareholder Rights Advocates at Levi & Korsinsky Investigate Humacyte, Inc. (HUMA) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Humacyte, Inc. (HUMA) Falls More Steeply Than Broader Market: What Investors Need to Know - MSN
Humacyte to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
Can Humacyte's Presentation at TD Cowen Conference Reveal New Bioengineered Tissue Breakthroughs? - StockTitan
Humacyte Shares Rise After Receiving US Patent for Bioreactor Manufacturing System - Marketscreener.com
Humacyte secures patent for bioreactor system until 2040 By Investing.com - Investing.com South Africa
Humacyte secures patent for bioreactor system until 2040 - Investing.com India
Humacyte announces issuance of U.S. patent covering Symvess manufacturing - TipRanks
Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues - The Manila Times
Can Humacyte's New Patent Transform Trauma Care? FDA-Approved Tissue Tech Now Protected Until 2040 - StockTitan
Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineHUMA - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Humacyte, Inc. (HUMA) And Encourages Stockholders to Reach Out - ACCESS Newswire
Promising Commercial Launch and Strategic Positioning Drive Buy Rating for Humacyte - TipRanks
Class Action Filed Against Humacyte, Inc. (HUMA) Seeking Recovery for Investors – Contact Levi & Korsinsky - ACCESS Newswire
Humacyte announces commercial launch of Symvess™ (acellular tissue engineered vessel-tyod) for extremity vascular trauma - PharmaLive
FDA approves Humacyte's Symvess for vascular injuries By Investing.com - Investing.com South Africa
Humacyte announces commercial launch of Symvess - TipRanks
FDA approves Humacyte’s Symvess for vascular injuries - Investing.com India
Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma - The Manila Times
FDA approves Humacyte's Symvess for vascular injuries - Investing.com
Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity - EIN News
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - ACCESS Newswire
Lost Money on Humacyte, Inc. (HUMA)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
When Will Humacyte, Inc. (NASDAQ:HUMA) Breakeven? - Yahoo Finance UK
Humacyte stock rallies 19% on FDA RMAT designation - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Humacyte, Inc. (HUMA) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Humacyte, Inc. to Contact the Firm Today! - ACCESS Newswire
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):